Overview of humotech

Our technology enables patients to trial different prosthetic feet before purchasing and fitting. While walking with our emulator system, they experience the mechanics of various foot options in real time, providing feedback to quickly identify the best option. Compared to traditional trial-and-error, we help get it right the first time, benefiting patients, providers, and payors.

Uniqueness: We are first to market with an emulation solution for the prosthetics and orthotics industry. Digital tools for healthcare decision-making are in high demand, and simulation or “digital twinning” has seen success in other medical domains. However, simulations of human movement with prosthetic feet lack predictive accuracy. Our tool combines the speed of digital design—rapidly emulating products via software and robotics—with the realism of walking on clinically validated robotic feet. Invented at Carnegie Mellon University, our technology is exclusively licensed, protected by five issued patents, with more pending.

Sustainability: Our solution helps patients achieve mobility goals and reduces prosthesis abandonment rates, currently 25%. Clinicians and payors benefit from standardized, objective evaluation procedures, replacing inefficient, subjective methods. Long-term, we address downstream impacts caused by poorly-selected prostheses, including reduced obesity, falls, and pain.

Profitability: Humotech operates with 65% gross margins and break-even EBITDA over nine years. R&D customers save time and resources by using our turnkey system. Clinical customers benefit from higher margins of advanced prosthetics sold and improved efficiency in billing, reimbursement, and patient outcomes, driving top-line revenue growth.

Clinicians fitting prosthetic feet for patients with lower limb amputations face a daunting challenge: navigating hundreds of foot models without objective tools or data to guide their decisions. This process often relies on intuition and experiential knowledge, which leads to inconsistencies in care. Compounding the issue is the retirement of many skilled prosthetists, creating a gap in expertise that impacts patient outcomes.

For patients, the consequences are profound. Individuals with prosthetic feet walk 65% slower than their peers and abandon their devices at a rate of 25%. When a prosthetic foot does not align with the patient’s needs, revisions are costly and time-intensive. Payors typically reimburse for a new foot only once every four years, meaning patients can be stuck with suboptimal devices for years. This lack of precision in fitting not only impacts mobility and quality of life but also leads to long-term health issues, such as increased risks of falls, chronic pain, and reduced activity levels.

The current trial-and-error approach is too imprecise, slow, and resource-intensive. Clinicians and payors expend significant effort navigating this outdated process, resulting in wasted time, money, and potential. By addressing the lack of standardized, data-driven methods, our solution ensures that the right prosthetic foot is selected the first time. This reduces costs, minimizes revisions, and improves outcomes for patients, providers, and payors alike, setting a new standard for prosthetic care.

As we expand into the clinical market, we are first targeting the approximately 3,000 prosthetics clinics in the U.S. A key strategic focus is on building a strong partnership with Hanger, the largest provider with 900+ locations. In parallel, we are segmenting non-Hanger clinics, prioritizing those selling 250+ prosthetic feet annually and led by forward-thinking owners interested in data-driven, outcomes-focused care. Throughout our proposed pilot we will develop a detailed strategy for marketing and selling our innovative solution, beginning with our first tradeshow exhibit at a prosthetics conference in Q12025: the American Association of Prosthetists & Orthotists.

Humotech sees transformative potential in forging partnerships with forward-thinking prosthetic clinics, integrated health systems, and national providers to advance the clinical application of the Caplex™ System. Our first clinical deployments are focused on high-volume prosthetic clinics—particularly those fitting over 250 feet per year—and are led by clinicians who prioritize data, outcomes, and innovation. A top priority is our ongoing engagement with Hanger Clinic, the largest prosthetic provider in the U.S. with over 900 locations, where a strategic partnership could accelerate adoption and standardization of our emulation-based approach nationwide. In parallel, we are piloting Caplex™ in select independent clinics to validate real-world outcomes, usability, and workflow integration.

Humotech’s long-standing collaborations with the Department of Defense (DoD) and the U.S. Department of Veterans Affairs (VA) serve as a bridge from research to clinic, demonstrating how federally funded R&D can inform and de-risk clinical innovation. These partnerships have enabled multiple clinical trials across top-tier rehabilitation centers like Walter Reed and VA Puget Sound, generating both regulatory-grade evidence and clinician buy-in. We are now working closely with clinical and regulatory experts, including Simbex and industry thought leaders, to navigate the FDA De Novo process and pilot a next-generation clinical decision-support tool rooted in real-world evidence.

Looking forward, we are actively exploring partnerships with health systems and payors who see value in value-based care models, where improving mobility outcomes while reducing costs is essential. Our platform can be integrated into payer workflows to justify reimbursement of higher-value prosthetic components, creating a data-backed case for medical necessity.

Together, these collaborations will drive broader adoption, generate critical real-world evidence, and redefine prosthetic care through precision, personalization, and performance—ultimately improving mobility and quality of life for individuals with limb loss across clinical settings.

We are seeking support from disAbled Life Alliance to help us connect with mission-aligned investors and strategic partners—such as clinics, health systems, and payors—who are eager to pilot innovative technologies that improve mobility outcomes for people living with limb loss. Humotech’s Caplex™ System enables individuals to “test drive” prosthetic feet and empowers clinicians with real-time data to make personalized, evidence-based decisions. With your network and leadership in advancing mobility, accessibility, and innovation for people with disabilities, we believe you can play a pivotal role in accelerating the adoption of this transformative technology. Together, we can drive forward a future where prosthetic care is more precise, equitable, and centered on the needs of each individual.